Company
Mononuclear Therapeutics (MonoTx™) Limited is a Biotechnology and Translational Medicine company that focuses on therapies based on cellular and non-cellular components found in umbilical cord blood and tissue. The Company’s primary focus is on neurological disorders, including chronic spinal cord injury (SCI), chronic stroke and age-related macular degeneration (AMD). Three million people have chronic SCI, 80 million people have chronic stroke, and 200 million people have AMD around the world. AMD is an eye disease that progresses over time and the leading cause of severe, permanent vision loss in people over age 60. The Company has close relationships with several premier research institutions in the USA and Hong Kong (HK) that conduct basic research, product development, and pre-clinical (animal) studies of these conditions. Discoveries in these institutions are transferred, validated and commercialized in MonoTx’s HK since 2016.
MonoTx HK began operations in 2016, and in late 2017, MonoTx started cord blood collection, processing, and banking to build mononuclear cell inventories for research and future therapeutic applications. In the last two years, MonoTx established the first public cord blood mononuclear cell bank in Hong Kong that is internationally accredited by Association for the Advancement of Blood & Biotherapies (AABB) and registered with the U.S. Food and Drug Administration (US FDA) Human Cell & Tissue Establishment Registry. In 2020, World Marrow Donor Association (WMDA), the world’s largest human hematopoietic cell registry, approved MonoTx application to list its cord blood cells for transplant physicians and patients to search and prescribe its HLA-matched cord blood cells for treatment. Recognition by these international organizations affirms the quality of MonoTx’s cells and indicate that MonoTx has met international clinical standards.
